Francisco Hernández, head of the clinical study, explained that at this stage “there will be a follow-up of all volunteers in order to detect positive symptomatic cases infected with the SARS-CoV-2 virus,” which “will allow us to determine the proportions of the study subjects who became ill according to the group: placebo or vaccinated.”